Mathematical Modeling of COVID-19 Epidemiology to Health Economics

Loading...

Media is loading
 

Document Type

Response or Comment

Publication Date

Summer 7-23-2021

Abstract

Patrick Smith, PharmD: Patrick has over 20 years of global drug development experience, and is currently Sr. Vice President of Commercial Strategy and Innovation at Certara, a company which is the global leader in the practice of model-informed drug development. A clinical pharmacologist by training, Dr. Smith has extensive experience in all phases of drug development, with particular expertise in infectious diseases and oncology, and has significant experience in applying modeling and simulation approaches to solve drug development challenges. He has led many drug development projects as a consultant for biotech and pharma companies, ranging from IND strategy, design and execution of entry-into-human and proof of concept studies, and crafting clinical pharmacology and clinical development plans. He has contributed to the approval of multiple drugs, and has extensive experience interacting with regulators globally, including regular attendance at meetings on behalf of clients at FDA, EMA, and PMDA.

Prior to Certara he was co-Founder and CSO of d3 Medicine (acquired by Certara), U.S. Head of Clinical Pharmacology at Roche, and an Associate Professor at the University at Buffalo School of Pharmacy and Roswell Park Cancer Institute. He received his PharmD at the University of California, San Francisco and completed a Clinical Residency at Duke University Medical Center. He has published more than 150 peer reviewed manuscripts in the scientific literature.

This document is currently not available here.

Share

COinS